308 related articles for article (PubMed ID: 14565783)
1. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).
Nelson M; Reid C; Beilin L; Donnan G; Johnston C; Krum H; Storey E; Tonkin A; McNeil J;
Drugs Aging; 2003; 20(12):897-903. PubMed ID: 14565783
[TBL] [Abstract][Full Text] [Related]
2. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
McNeil JJ; Wolfe R; Woods RL; Tonkin AM; Donnan GA; Nelson MR; Reid CM; Lockery JE; Kirpach B; Storey E; Shah RC; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Johnston CI; Ryan J; Radziszewska B; Jelinek M; Malik M; Eaton CB; Brauer D; Cloud G; Wood EM; Mahady SE; Satterfield S; Grimm R; Murray AM;
N Engl J Med; 2018 Oct; 379(16):1509-1518. PubMed ID: 30221597
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population.
Lewis JP; Riaz M; Xie S; Polekhina G; Wolfe R; Nelson M; Tonkin AM; Reid CM; Murray AM; McNeil JJ; Shuldiner AR; Lacaze P
Clin Pharmacol Ther; 2020 Dec; 108(6):1289-1298. PubMed ID: 32562573
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for the prevention of cardiovascular events in the elderly.
Mahé I; Leizorovicz A; Caulin C; Bergmann JF
Drugs Aging; 2003; 20(13):999-1010. PubMed ID: 14561103
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
7. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
ASPREE Investigator Group
Contemp Clin Trials; 2013 Nov; 36(2):555-64. PubMed ID: 24113028
[TBL] [Abstract][Full Text] [Related]
8. Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview.
Lippi G; Danese E; Favaloro EJ
Semin Thromb Hemost; 2019 Mar; 45(2):157-163. PubMed ID: 30347414
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
[TBL] [Abstract][Full Text] [Related]
10. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.
McNeil JJ; Woods RL; Nelson MR; Murray AM; Reid CM; Kirpach B; Storey E; Shah RC; Wolfe RS; Tonkin AM; Newman AB; Williamson JD; Lockery JE; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Trevaks RE; Orchard SG; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Grimm RH;
J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1586-1593. PubMed ID: 28329340
[TBL] [Abstract][Full Text] [Related]
11. Role of aspirin in primary prevention of cardiovascular disease.
Patrono C; Baigent C
Nat Rev Cardiol; 2019 Nov; 16(11):675-686. PubMed ID: 31243390
[TBL] [Abstract][Full Text] [Related]
12. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
[TBL] [Abstract][Full Text] [Related]
13. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
14. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Rothwell PM; Cook NR; Gaziano JM; Price JF; Belch JFF; Roncaglioni MC; Morimoto T; Mehta Z
Lancet; 2018 Aug; 392(10145):387-399. PubMed ID: 30017552
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for the primary prevention of cardiovascular events.
Colwell JA
Drugs Today (Barc); 2006 Jul; 42(7):467-79. PubMed ID: 16894401
[TBL] [Abstract][Full Text] [Related]
16. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly).
Silagy CA; McNeil JJ; Donnan GA; Tonkin AM; Worsam B; Campion K
J Am Geriatr Soc; 1994 Jun; 42(6):643-7. PubMed ID: 8201151
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study.
Nelson MR; Reid CM; Ames DA; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Krum H; Storey E; Tonkin A; Wolfe R; Woods R; McNeil JJ
Med J Aust; 2008 Jul; 189(2):105-9. PubMed ID: 18637782
[TBL] [Abstract][Full Text] [Related]
18. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
19. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
20. Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
McNeil JJ; Woods RL; Nelson MR; Reid CM; Kirpach B; Wolfe R; Storey E; Shah RC; Lockery JE; Tonkin AM; Newman AB; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Ryan J; Radziszewska B; Grimm R; Murray AM;
N Engl J Med; 2018 Oct; 379(16):1499-1508. PubMed ID: 30221596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
